GSK revises Relenza prescribing information to warn of abnormal behavior
April 4, 2008
GlaxoSmithKline updates Warnings and Precautions sections of zanamivir prescribing information
GSK revises Relenza prescribing information to warn of abnormal behaviorPostmarketing reports of delirium and abnormal behavior in patients with influenza who are receiving neuraminidase inhibitors have prompted GlaxoSmithKline to update the prescribing information for zanamivir (Tamiflu), another neuraminidase inhibitor, to include the same warnings.
